目的 探討鎮(zhèn)腦寧膠囊聯(lián)合氯沙坦鉀片治療原發(fā)性高血壓的臨床效果。方法 選取2017年8月—2020年8月于平頂山市新華區(qū)人民醫(yī)院診療的106例原發(fā)性高血壓患者，根據(jù)入院順序分成對照組和治療組，每組分別53例。對照組口服氯沙坦鉀片，50 mg/次，1次/d；治療組患者在對照組基礎(chǔ)上口服鎮(zhèn)腦寧膠囊，1.2 g/次，3次/d。兩組患者均連續(xù)治療8周。觀察兩組患者臨床療效，比較治療前后兩組患者24 h平均收縮壓和平均舒張壓，及血清N-端腦利鈉肽前體（NT-proBNP）、血管性血友病因子（vWF）水平和尿微量白蛋白水平。結(jié)果 治療后，治療組總有效率為96.23%，明顯高于對照組的84.91%（P<0.05）；治療后，兩組患者24 h平均收縮壓和24 h平均舒張壓均顯著下降（P<0.05），且治療組明顯低于對照組（P<0.05）；治療后，兩組患者血清NT-proBNP、vWF水平和尿微量白蛋白水平均顯著下降（P<0.05），且治療組明顯低于對照組（P<0.05）。結(jié)論 鎮(zhèn)腦寧膠囊聯(lián)合氯沙坦鉀片治療原發(fā)性高血壓療效顯著，能夠有效控制患者動態(tài)血壓水平，降低血清學(xué)指標水平，安全性高，具有一定臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Zhennaoning Capsules combined with losartan potassium in treatment of essential hypertension. Methods Patients (106 cases) with essential hypertension in Pingdingshan Xinhua District People's Hospital from August 2017 to August 2020 were divided into control and treatment groups according to the order of admission, and each group had 53 cases. Patients in the control group were po administered with Losartan Potassium Tablets, 50 mg/time, once daily. Patients in the treatment group were po administered with Zhennaoning Capsules on the basis of the control group, 1.2 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the 24 h mean systolic blood pressure and mean diastolic blood pressure, the serum NT-proBNP, vWF and urinary microalbumin levels in two groups before and after treatment were compared. Results After treatment, the total clinical effective rate of the treatment group was 96.23%, which was significantly higher than 84.91% of the control group (P < 0.05). After treatment, 24 h average systolic blood pressure and 24 h average diastolic blood pressure were significantly decreased in two groups (P < 0.05), and which in the treatment group was significantly lower than those in the control group (P < 0.05). After treatment, the levels of serum NT-proBNP, vWF and urinary microalbumin in two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Zhennaoning Capsules combined with losartan potassium has significant curative effect in treatment of essential hypertension, can effectively control the level of ambulatory blood pressure and reduce the level of serological indexes with high safety, which has a certain clinical application value.

R971